Does treating subclinical hypothyroidism improve markers of cardiovascular risk?

Treatments in Endocrinology

Volumn 5, Issue 2, 2006, Pages 65-81

  Monzani, Fabio ^a   Dardano, Angela ^a   Caraccio, Nadia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; CHOLESTEROL; CYCLOOXYGENASE 2 INHIBITOR; LEVOTHYROXINE; LIPID; LIPOPROTEIN; THYROTROPIN; THYROXINE;

ATHEROSCLEROSIS; AUTOPSY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFICACY; EUTHYROIDISM; HEART DISEASE; HUMAN; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; SYSTEMIC VASCULAR RESISTANCE; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; PROSPECTIVE STUDY; RISK FACTOR;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; HUMANS; HYPOTHYROIDISM; PROSPECTIVE STUDIES; RISK FACTORS; THYROTROPIN; THYROXINE;

EID: 33645070547     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605020-00001     Document Type: Review

References (203)

1. Ross DS. Subclinical hypothyroidism. In: Braveman LE, Utiger RD, editors. Werner and Ingbar's the thyroid: a fundamental and clinical text. 8th ed. New York: Lippincott Williams and Wilkins, 2000: 1001-6
2. Andersen S, Pedersen KM, Bruun NH, et al. Narrow individual variations in serum T (4) and T (3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002; 87 (3): 1068-72
3. Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004; 24: 1-13
4. Cooper DS. Clinical practice: subclinical hypothyroidism. N Engl J Med 2001; 345 (4): 260-5
5. Owen PJ, Lazarus JH. Subclinical hypothyroidism: the case for treatment. Trends Endocrinol Metab 2003; 14 (6): 257-61
6. Lekakis J, Papamichael C, Alevizaki M, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997; 7 (3): 411-4
7. Bindels AJ, Westendorp RG, Frolich M, et al. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? Clin Endocrinol (Oxf) 1999; 50 (2): 217-20
8. Faber J, Petersen L, Wiinberg N, et al. Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism. Thyroid 2002; 12 (4): 319-24
9. Fazio S, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004; 59: 31-50
10. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291 (2): 228-38
11. Cooper DS. Subclinical thyroid disease: a clinician's perspective. Ann Intern Med 1998; 129 (2): 135-8
12. Cushing GW. Subclinical hypothyroidism: understanding is the key to decision making. Postgrad Med 1993; 94 (1): 95-7, 100-2, 106-7
13. Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292 (21): 2591-9
14. Rivolta G, Cerutti R, Colombo R, et al. Prevalence of subclinical hypothyroidism in a population living in the Milan metropolitan area. J Endocrinol Invest 1999; 22 (9): 693-7
15. Kanaya AM, Harris F, Volpato S, et al. Association between thyroid dysfunction and total cholesterol level in an older biracial population: the health, aging and body composition study. Arch Intern Med 2002; 162 (7): 773-9
16. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996; 42 (1): 140-5
17. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43 (1): 55-68
18. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7 (6): 481-93
19. Sawin CT, Castelli WP, Hershman JM, et al. The aging thyroid: thyroid deficiency in the Framingham Study. Arch Intern Med 1985; 145 (8): 1386-8
20. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997; 26 (1): 189-218
21. Samuels MH. Subclinical thyroid disease in the elderly. Thyroid 1998; 8 (9): 803-13
22. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87 (2): 489-99
23. Robuschi G, Safran M, Braverman LE, et al. Hypothyroidism in the elderly. Endocr Rev 1987; 8 (2): 142-53
24. Kung AW, Janus ED. Thyroid dysfunction in ambulatory elderly Chinese subjects in an area of borderline iodine intake. Thyroid 1996; 6 (2): 111-4
25. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med 2000; 160 (4): 526-34
26. Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34 (1): 77-83
27. Sawin CT, Chopra D, Azizi F, et al. The aging thyroid: increased prevalence of elevated serum thyrotropin levels in the elderly. JAMA 1979; 242 (3): 247-50
28. Campbell AJ, Reinken J, Allan BC. Thyroid disease in the elderly in the community. Age Ageing 1981; 10 (1): 47-52
29. Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87 (7): 3221-6
30. Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab 2004; 89 (10): 4890-7
31. Helfand M, Redfern CC. Clinical guideline, part 2: screening for thyroid disease: an update. American College of Physicians. Ann Intern Med 1998; 129 (2): 144-58
32. Kumana CR, Cheung BM, Lauder IJ. Gauging the impact of statins using number needed to treat. JAMA 1999; 282 (20): 1899-901
33. Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005; 90 (1): 581-5
34. Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000; 160: 1573-5
35. American Academy of Family Physicians. Summary of policy recommendations for periodic health examinations. Lewood (KS): American Academy of Family Physicians, 2002
36. American College of Obstetrics and Gynecology ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2002; 100: 387-96
37. American College of Physicians clinical guideline: I. Screening for thyroid disease. Ann Intern Med 1998; 129: 141-3
38. US Preventive Services Task Force. Screening for thyroid disease: guide to clinical preventive services. 2nd ed. Baltimore (MD): Williams & Wilkins, 1996
39. Vanderpump MP, Ahlquist JA, Franklyn JA, et al. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism: the Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicans of London, and the Society for Endocrinology. BMJ 1996; 313: 539-44
40. American Association of Clinical Endocrinologists and the American College of Endocrinology AACE clinical practice guidelines for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 1995; 1: 56-62
41. Beaulieu MD. Screening for thyroid disorders and thyroid cancer asymptomatic adults. In: Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa (ON): Health Canada, 1994: 612-8
42. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344 (7): 501-9
43. Hamilton MA, Stevenson LW, Luu M, et al. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 1990; 16 (1): 91-5
44. Klein I, Ojamaa K. Thyroid hormone treatment of congestive heart failure. Am J Cardiol 1998; 81 (4): 490-1
45. Bettendorf M, Schmidt KG, Tiefenbacher U, et al. Transient secondary hypothyroidism in children after cardiac surgery. Pediatr Res 1997; 41 (3): 375-9
46. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995; 333 (23): 1522-7
47. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med 1990; 88 (6): 626-30
48. Everts ME, Verhoeven FA, Bezstarosti K, et al. Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology 1996; 137 (10): 4235-42
49. Brent GA. The molecular basis of thyroid hormone action. N Engl J Med 1994; 331 (13): 847-53
50. Ojamaa K, Klemperer JD, MacGilvray SS, et al. Thyroid hormone and hemodynamic regulation of beta-myosin heavy chain promoter in the heart. Endocrinology 1996; 137 (3): 802-8
51. Morkin E. Regulation of myosin heavy chain genes in the heart. Circulation 1993; 87 (5): 1451-60
52. Kiss E, Jakab G, Kranias EG, et al. Thyroid hormone-induced alterations in phospholamban protein expression: regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res 1994; 75 (2): 245-51
53. Davis PJ, Davis FB. Acute cellular actions of thyroid hormone and myocardial function. Ann Thorac Surg 1993; 56 (1 Suppl.): S16-23
54. Walker JD, Crawford FA, Kato S, et al. The novel effects of 3,5,3′-triiodo-L-thyronine on myocyte contractile function and beta-adrenergic responsiveness in dilated cardiomyopathy. J Thorac Cardiovasc Surg 1994; 108 (4): 672-9
55. Ojamaa K, Kenessey A, Klein I. Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. Endocrinology 2000; 141 (6): 2139-44
56. Levey GS, Klein I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am J Med 1990; 88 (6): 642-6
57. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996; 6 (5): 505-12
58. Park KW, Dai HB, Ojamaa K, et al. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 1997; 85 (4): 734-8
59. Mizuma H, Murakami M, Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 2001; 88 (3): 313-8
60. Napoli R, Biondi B, Guardasole V, et al. Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation 2001; 104 (25): 3076-80
61. Biondi B, Fazio S, Palmieri EA, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1999; 84 (6): 2064-7
62. Di Bello V, Monzani F, Giorgi D, et al. Ultrasonic myocardial textural analysis in subclinical hypothyroidism. J Am Soc Echocardiogr 2000; 13 (9): 832-40
63. Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab 2001; 86 (3): 1110-5
64. Vitale G, Galderisi M, Lupoli GA, et al. Left ventricular myocardial impairment in subclinical hypothyroidism assessed by a new ultrasound tool: pulsed tissue Doppler. J Clin Endocrinol Metab 2002; 87 (9): 4350-5
65. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000; 10 (8): 665-79
66. Luboshitzky R, Aviv A, Herer P, et al. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002; 12 (5): 421-5
67. Cooper DS, Halpern R, Wood LC, et al. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. Ann Intern Med 1984; 101 (1): 18-24
68. Bell GM, Todd WT, Forfar JC, et al. End-organ responses to thyroxine therapy in subclinical hypothyroidism. Clin Endocrinol (Oxf) 1985; 22 (1): 83-9
69. Nystrom E, Caidahl K, Fager G, et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin Endocrinol (Oxf) 1988; 29 (1): 63-75
70. Arem R, Rokey R, Kiefe C, et al. Cardiac systolic and diastolic function at rest and exercise in subclinical hypothyroidism: effect of thyroid hormone therapy. Thyroid 1996; 6 (5): 397-402
71. Brenta G, Mutti LA, Schnitman M, et al. Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy. Am J Cardiol 2003; 91 (11): 1327-30
72. Yazici M, Gorgulu S, Sertbas Y, et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. Int J Cardiol 2004; 95 (2-3): 135-43
73. Biondi B, Palmieri EA, Lombardi G, et al. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002; 137: 904-14
74. Bough EW, Crowley WF, Ridgway C, et al. Myocardial function in hypothyroidism: relation to disease severity and response to treatment. Arch Intern Med 1978; 138 (10): 1476-80
75. Ridgway EC, Cooper DS, Walker H, et al. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1981; 53 (6): 1238-42
76. Forfar JC, Wathen CG, Todd WT, et al. Left ventricular performance in subclinical hypothyroidism. Q J Med 1985; 57 (224): 857-65
77. Foldes J, Istvanfy M, Halmagyi M, et al. Hypothyroidism and the heart: examination of left ventricular function in subclinical hypothyroidism. Acta Med Hung 1987; 44 (4): 337-47
78. Tseng KH, Walfish PG, Persaud JA, et al. Concurrent aortic and mitral valve echocardiography permits measurement of systolic time intervals as an index of peripheral tissue thyroid functional status. J Clin Endocrinol Metab 1989; 69 (3): 633-8
79. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med 1992; 92 (6): 631-42
80. Amidi M, Leon DF, DeGroot WJ, et al. Effect of the thyroid state on myocardial contractility and ventricular ejection rate in man. Circulation 1968; 38 (2): 229-39
81. Polikar R, Burger AG, Scherrer U, et al. The thyroid and the heart. Circulation 1993; 87 (5): 1435-41
82. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system: from theory to practice. J Clin Endocrinol Metab 1994; 78 (5): 1026-7
83. Ooi TC, Whitlock RM, Frengley PA, et al. Systolic time intervals and ankle reflex time in patients with minimal serum TSH elevation: response to triiodothyronine therapy. Clin Endocrinol (Oxf) 1980; 13 (6): 621-7
84. Bastenie PA, Vanhaelst L, Neve P. Coronary-artery disease in hypothyroidism. Lancet 1967; II (7528): 1221-2
85. Bastenie PA, Vanhaelst L, Bonnyns M, et al. Preclinical hypothyroidism: a risk factor for coronary heart-disease. Lancet 1971; I (7692): 203-4
86. Fowler PB, Swale J, Andrews H. Hypercholesterolaemia in borderline hypothyroidism: stage of premyxoedema. Lancet 1970; II (7671): 488-91
87. Tieche M, Lupi GA, Gutzwiller F, et al. Borderline low thyroid function and thyroid autoimmunity: risk factors for coronary heart disease? Br Heart J 1981; 46 (2): 202-6
88. Mya MM, Aronow WS. Subclinical hypothyroidism is associated with coronary artery disease in older persons. J Gerontol A Biol Sci Med Sci 2002; 57 (10): M658-9
89. Powell J, Zadeh JA, Carter G, et al. Raised serum thyrotrophin in women with peripheral arterial disease. Br J Surg 1987; 74 (12): 1139-41
90. Miura S, Iitaka M, Suzuki S, et al. Decrease in serum levels of thyroid hormone in patients with coronary heart disease. Endocr J 1996; 43 (6): 657-63
91. Tunbridge WM, Evered DC, Hall R, et al. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure. Clin Endocrinol (Oxf) 1977; 7 (6): 495-508
92. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88 (6): 2438-44
93. Vanderpump MP, Tunbridge WM, French JM, et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996; 6 (3): 155-60
94. Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000; 132 (4): 270-8
95. Nagataki S, Shibata Y, Inoue S, et al. Thyroid diseases among atomic bomb survivors in Nagasaki. JAMA 1994; 272 (5): 364-70
96. Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89 (7): 3365-70
97. Kvetny J, Heldgaard PE, Bladbjerg EM, et al. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf) 2004; 61 (2): 232-8
98. Lindeman RD, Romero LJ, Schade DS, et al. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid 2003; 13 (6): 595-600
99. Ooka H, Fujita S, Yoshimoto E. Pituitary-thyroid activity and longevity in neonatally thyroxine-treated rats. Mech Ageing Dev 1983; 22 (2): 113-20
100. Flurkey K, Papaconstantinou J, Harrison DE. The Snell dwarf mutation Pit1 (dw) can increase life span in mice. Mech Ageing Dev 2002; 123 (2-3): 121-30
101. Cooper DS. Thyroid disease in the oldest old: the exception to the rule. JAMA 2004; 292 (21): 2651-4
102. Luscher TF, Vanhoutte PM, The endothelium: modulator of cardiovascular function. Boca Raton (FL): CRC Press, 1990
103. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288 (5789): 373-6
104. Abdu TA, Elhadd T, Pfeifer M, et al. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 2001; 12 (6): 257-65
105. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327 (6122): 524-6
106. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333 (6174): 664-6
107. Bredt DS, Hwang PM, Glatt CE, et al. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351 (6329): 714-8
108. Taddei S, Virdis A, Ghiadoni L, et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97 (22): 2222-9
109. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101 (9): 948-54
110. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101 (16): 1899-906
111. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104 (22): 2673-8
112. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39 (2): 257-65
113. Cikim AS, Oflaz H, Ozbey N, et al. Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid 2004; 14 (8): 605-9
114. Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003; 88 (8): 3731-7
115. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound: ARIC Investigators. Stroke 1993; 24 (9): 1297-304
116. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90 (10C): 18L-21L
117. Allan PL, Mowbray PI, Lee AJ, et al. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease: the Edinburgh Artery Study. Stroke 1997; 28 (2): 348-53
118. Salonen R, Salonen JT. Determinants of carotid intima-media thickness: a population-based ultrasonography study in Eastern Finnish men. J Intern Med 1991; 229 (3): 225-31
119. Gnasso A, Pujia A, Irace C, et al. Increased carotid arterial wall thickness in common hyperlipidemia. Coron Artery Dis 1995; 6 (1): 57-63
120. Gnasso A, Irace C, Mattioli PL, et al. Carotid intima-media thickness and coronary heart disease risk factors. Atherosclerosis 1996; 119 (1): 7-15
121. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia: ultrasound measurement of intima-media thickness in the common carotid artery. Arterioscler Thromb 1992; 12 (1): 70-7
122. Bots ML, Hofman A, de Bruyn AM, et al. Isolated systolic hypertension and vessel wall thickness of the carotid artery: the Rotterdam Elderly Study. Arterioscler Thromb 1993; 13 (1): 64-9
123. Kawamori R, Yamasaki Y, Matsushima H, et al. Prevalence of carotid atherosclerosis in diabetic patients: ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 1992; 15 (10): 1290-4
124. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96 (5): 1432-7
125. Mannami T, Konishi M, Baba S, et al. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita Study. Stroke 1997; 28 (3): 518-25
126. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 1995; 26 (3): 386-91
127. Nagasaki T, Inaba M, Henmi Y, et al. Decrease in carotid intima-media thickness in hypothyroid patients after normalization of thyroid function. Clin Endocrinol (Oxf) 2003; 59 (5): 607-12
128. Monzani F, Caraccio N, Kozakowa M, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2004; 89 (5): 2099-106
129. Parving HH, Hansen JM, Nielsen SL, et al. Mechanisms of edema formation in myxedema: increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med 1979; 301 (9): 460-5
130. Arem R, Escalante DA, Arem N, et al. Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein (a). Metabolism 1995; 44 (12): 1559-63
131. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004; 363 (9411): 793-803
132. Kinlaw WB. Atherosclerosis and the thyroid. Thyroid Today 1991; 14: 1-8
133. Geul KW, van Sluisveld IL, Grobbee DE, et al. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: associations with serum lipids. Clin Endocrinol (Oxf) 1993; 39 (3): 275-80
134. Vierhapper H, Nardi A, Grosser P, et al. Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid 2000; 10 (11): 981-4
135. Hueston WJ, Pearson WS. Subclinical hypothyroidism and the risk of hypercholesterolemia. Ann Fam Med 2004; 2 (4): 351-5
136. Bauer DC, Ettinger B, Browner WS. Thyroid functions and serum lipids in older women: a population-based study. Am J Med 1998; 104 (6): 546-51
137. Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf) 1996; 44 (6): 643-9
138. Bogner U, Arntz HR, Peters H, et al. Subclinical hypothyroidism and hyperlipoproteinaemia: indiscriminate L-thyroxine treatment not justified. Acta Endocrinol (Copenh) 1993; 128 (3): 202-6
139. Efstathiadou Z, Bitsis S, Milionis HJ, et al. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J Endocrinol 2001; 145 (6): 705-10
140. Yildirimkaya M, Ozata M, Yilmaz K, et al. Lipoprotein (a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapy. Endocr J 1996; 43 (6): 731-6
141. Kung AW, Pang RW, Janus ED. Elevated serum lipoprotein (a) in subclinical hypothyroidism. Clin Endocrinol (Oxf) 1995; 43 (4): 445-9
142. Miura S, Iitaka M, Yoshimura H, et al. Disturbed lipid metabolism in patients with subclinical hypothyroidism: effect of L-thyroxine therapy. Intern Med 1994; 33 (7): 413-7
143. Caron P, Calazel C, Parra HJ, et al. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. Clin Endocrinol (Oxf) 1990; 33 (4): 519-23
144. Forga L, Iriarte A, Calderon DM, et al. Lipidic changes in subclinical hypothyroidism: evolution according to whether or not corrections are made of TSH levels. An Sist Sanit Navar 1998; 21 (3): 313-8
145. Muller B, Tsakiris DA, Roth CB, et al. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 2001; 31 (2): 131-7
146. Tagliaferri M, Berselli ME, Calo G, et al. Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile. Obes Res 2001; 9 (3): 196-201
147. Luboshitzky R, Herer P. Cardiovascular risk factors in middle-aged women with subclinical hypothyroidism. Neuro Endocrinol Lett 2004; 25 (4): 262-6
148. Tzotzas T, Krassas GE, Konstantinidis T, et al. Changes in lipoprotein (a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10 (9): 803-8
149. Lithell H, Boberg J, Hellsing K, et al. Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase activity in overt and subclinical hypothyroidism: the effect of substitution therapy. Eur J Clin Invest 1981; 11 (1): 3-10
150. Diekman T, Lansberg PJ, Kastelein JJ, et al. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 1995; 155 (14): 1490-5
151. Romaldini JH, Biancalana MM, Figueiredo DI, et al. Effect of L-thyroxine administration on antithyroid antibody levels, lipid profile, and thyroid volume in patients with Hashimoto's thyroiditis. Thyroid 1996; 6 (3): 183-8
152. Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol 1998; 138 (2): 141-5
153. Danese MD, Ladenson PW, Meinert CL, et al. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85 (9): 2993-3001
154. Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double-blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86 (10): 4860-6
155. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002; 87 (4): 1533-8
156. Kong WM, Sheikh MH, Lumb PJ, et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med 2002; 112 (5): 348-54
157. Milionis HJ, Efstathiadou Z, Tselepis AD, et al. Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid 2003; 13 (4): 365-9
158. Perez A, Cubero JM, Sucunza N, et al. Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism. Metabolism 2004; 53 (11): 1512-5
159. Ito M, Takamatsu J, Sasaki I, et al. Disturbed metabolism of remnant lipoproteins in patients with subclinical hypothyroidism. Am J Med 2004; 117 (9): 696-9
160. Canturk Z, Cetinarslan V, Tarkun I, et al. Lipid profile and lipoprotein(a) a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Endocrine Res 2003: 29: 307-16
161. Serter R, Demirbas B, Korukluoglu B, et al. The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism. J Endocrinol Invest 2004; 27: 897-903
162. Jaeschke R, Guyatt G, Gerstein H, et al. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996; 11 (12): 744-9
163. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308 (6925): 367-72
164. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260 (5): 641-51
165. Sundaram V, Hanna AN, Koneru L, et al. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. J Clin Endocrinol Metab 1997; 82 (10): 3421-4
166. Diekman T, Demacker PN, Kastelein JJ, et al. Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab 1998; 83 (5): 1752-5
167. Duntas LH, Mantzou E, Koutras DA. Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 2002; 12 (11): 1003-7
168. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88 (6): 2762-70
169. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994; 5 (2): 102-9
170. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996; 276 (7): 544-8
171. Surks MI, Ocampo E. Subclinical thyroid disease. Am J Med 1996; 100 (2): 217-23
172. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332 (10): 635-41
173. Ma J, Hennekens CH, Ridker PM, et al. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999; 33 (5): 1347-52
174. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290 (7): 932-40
175. Martinez-Triguero ML, Hernandez-Mijares A, Nguyen TT, et al. Effect of thyroid hormone replacement on lipoprotein (a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clin Proc 1998; 73 (9): 837-41
176. Pazos F, Alvarez JJ, Rubies-Prat J, et al. Long-term thyroid replacement therapy and levels of lipoprotein (a) and other lipoproteins. J Clin Endocrinol Metab 1995; 80 (2): 562-6
177. Tsimihodimos V, Bairaktari E, Tzallas C, et al. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 1999; 9 (4): 365-8
178. Ganotakis ES, Mandalaki K, Tampakaki M, et al. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy. Angiology 2003; 54 (5): 569-76
179. Lotz H, Salabe GB. Lipoprotein (a) increase associated with thyroid autoimmunity. Eur J Endocrinol 1997; 136 (1): 87-91
180. Nygard O, Refsum H, Ueland PM, et al. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67 (2): 263-70
181. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270 (22): 2693-8
182. Hoffer LJ, Robitaille L, Elian KM, et al. Plasma reduced homocysteine concentrations are increased in end-stage renal disease. Kidney Int 2001; 59 (1): 372-7
183. Hussein WI, Green R, Jacobsen DW, et al. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med 1999; 131 (5): 348-51
184. Diekman MJ, van der Put NM, Blom HJ, et al. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol (Oxf) 2001; 54 (2): 197-204
185. Ingenbleek Y, Barclay D, Dirren H. Nutritional significance of alterations in serum amino acid patterns in goitrous patients. Am J Clin Nutr 1986; 43 (2): 310-9
186. Christ-Crain M, Meier C, Guglielmetti M, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003; 166 (2): 379-86
187. Deicher R, Vierhapper H. Homocysteine: a risk factor for cardiovascular disease in subclinical hypothyroidism? Thyroid 2002; 12 (8): 733-6
188. Marqusee E, Mandel SJ. The blood in hypothyroidism. In: Braveman LE, Utiger RD, editors. Werner and Ingbar's the thyroid: a fundamental and clinical text. 8th ed. New York: Lippincott Williams and Wilkins, 2000: 800-2
189. Canturk Z, Cetinarslan B, Tarkun I, et al. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2003; 13 (10): 971-7
190. Chadarevian R, Bruckert E, Leenhardt L, et al. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001; 86 (2): 732-7
191. Chadarevian R, Bruckert E, Giral P, et al. Relationship between thyroid hormones and fibrinogen levels. Blood Coagul Fibrinolysis 1999; 10 (8): 481-6
192. Rennie JA, Bewsher PD, Murchison LE, et al. Coagulation and fibrinolysis in thyroid disease. Acta Haematol 1978; 59 (3): 171-7
193. Ford HC, Carter JM. Haemostasis in hypothyroidism. Postgrad Med J 1990; 66 (774): 280-4
194. Dalton RG, Dewar MS, Savidge GF, et al. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1987; I (8540): 1007-9
195. Tachman ML, Guthrie Jr GP. Hypothyroidism: diversity of presentation. Endocr Rev 1984; 5 (3): 456-65
196. Masunaga R, Nagasaka A, Nakai A, et al. Alteration of platelet aggregation in patients with thyroid disorders. Metabolism 1997; 46 (10): 1128-31
197. Hellem AJ, Segaard E, Solem JH. The adhesiveness of human blood platelets and thyroid function. Acta Med Scand 1975; 197 (1-2): 15-7
198. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 (14): 973-9
199. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342 (12): 836-43
200. Dardano A, Caraccio N, Virdis A, et al. Systemic inflammation and endothelial dysfunction in patients with Hashimoto's thyroiditis and subclinical hypothyroidism [abstract]. J Endocrinol Invest 2004; 27 Suppl. 5: S15
201. Wang HC, Dragoo J, Zhou Q, et al. An intrinsic thyrotropin-mediated pathway of TNF-alpha production by bone marrow cells. Blood 2003; 101 (1): 119-23
202. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341 (8): 549-55
203. Lincoln SR, Ke RW, Kutteh WH. Screening for hypothyroidism in infertile women. J Reprod Med 1999; 44 (5): 455-7